Status:
COMPLETED
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen
Lead Sponsor:
Fondazione Italiana Linfomi - ETS
Conditions:
B-Cell Lymphomas
Eligibility:
All Genders
18+ years
Brief Summary
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic facto...
Eligibility Criteria
Inclusion
- Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007.
- Any stage of disease.
- Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).
- Age at least 18 years.
- Availability of tissue biopsy at diagnosis for a possible centralized revision.
- Availability of data on clinical involvement, laboratory, treatment and follow up.
Exclusion
- None
Key Trial Info
Start Date :
May 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
1927 Patients enrolled
Trial Details
Trial ID
NCT01478269
Start Date
May 1 2009
End Date
May 1 2011
Last Update
November 23 2011
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Hemocentro-Unicamp
Campinas, Brazil
2
Centro Medico
Santa Isabel, Brazil
3
Centro Paulista de Oncologia
São Paulo, Brazil
4
Santa Casa Medical School
São Paulo, Brazil